Back

Clinical profiles for and treatment options for diuretic resistance in heart failure

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy 5 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nahikari Salterain Gonzalez

Navarra University Clinic, Pamplona (Spain)

7 More presentations in this session

Presentation thumbnail
Clinical practice associated with 6-month use of patiromer in patients with heart failure
Doctor I. ARAUJO (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Remote monitoring in a virtual ward safely facilitates the rapid up-titration of prognostic medication for heart failure with reduced ejection fraction patients
Doctor A. Kirupananthavel (London, GB)
Abstract Slides Video
Presentation thumbnail
Single centre 3-year experience in intermittent levosimendan infusion
Doctor F. Gerardo (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
SGLT2i on transthyretin amyloid cardiomyopathy - a new drug for an under-recognized cardiomyopathy
Mr D. Inacio Cazeiro (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Initial experience of vericiguat treatment in patients with heart failure and high risk of decompensation.
Doctor M. Groba Marco (Las Palmas de Gran Canaria, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy 5

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Acute heart failure patients with diuretic resistance: who are they and prognostic implications of diuretic resistance. The experience of a general hospital
thumbnail
Congress Presentation
Diuretic resistance and the efficacy of hydrochlorothiazide in acute decompensated heart failure: a post-hoc analysis of the CLOROTIC Trial
thumbnail
Congress Presentation
The early evaluation of diuretic resistance as recommended by ESC Guidelines predicts long-term outcomes in patients with acute heart failure.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources